As Spectral Med Inc prepares to release its latest earnings report, investors are closely watching for signs of progress in the challenging biotechnology sector.
Scheduled for release on August 7, 2026, before the market opens, Spectral Med Inc (EDT.TO) will report its earnings for the fiscal period ending June 30, 2026. With an EPS estimate of -$0.01, this report is crucial for investors looking to assess the company's financial health and its path toward FDA approval for its PMX treatment.
Recent earnings trend
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$410.79M
52W high
$1.84
52W low
$0.81
1W change
+0.72%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 125.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+125.0% Upside
Current Price
C$1.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
26.7%
Annualized
90-Day Vol
28.9%
Annualized
Trend (90d)
-8.9%
Annualized drift
90d Mean
C$1.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.39 | C$1.26 – C$1.52 |
| 60 trading days | C$1.37 | C$1.20 – C$1.56 |
| 90 trading days | C$1.36 | C$1.16 – C$1.59 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 1 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-07 | — | -0.0100 | — |
| 2026-03-31 | 2026-05-08 | -0.0100 | -0.0100 | +0.0% |
| 2025-12-31 | 2026-03-26 | -0.0100 | -0.0200 | +50.0% |
| 2025-09-30 | 2025-11-07 | -0.1100 | -0.0100 | -1000.0% |
| 2025-06-30 | 2025-08-08 | -0.0068 | — | — |
| 2025-03-31 | 2025-05-09 | -0.0443 | — | — |
Advertisement
Investor takeaway: Investors should pay attention to whether Spectral meets or exceeds its EPS estimates, especially given its recent mixed results. The upcoming report will shed light on its revenue growth and operational progress, particularly after significant milestones in its clinical trials.
EPS Estimate: -$0.01
With a consensus EPS estimate of -$0.01, all eyes will be on Spectral's ability to improve its financial performance after a recent string of losses.
Bull case
If Spectral Med meets or exceeds its EPS estimate, it could indicate operational improvements and boost investor confidence, especially as the company inches closer to FDA approval for its PMX treatment.
Bear case
On the flip side, if the company fails to meet EPS expectations, it might raise concerns about its financial trajectory and ability to secure future funding, particularly as it navigates the complexities of the biotechnology landscape.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
